BA, MD, PhD
Health Science Clinical Professor at the School of Medicine, University of California, Irvine.
He completed his MD and PhD at the University of Texas Southwestern Medical School and has been awarded the Best Doctors in America® (Medical Oncology and Haematology) award on three occasions (2011–2013).
Published extensively in the field of oncology
Clinical interests include oesophageal, gastric, head and neck, liver, lung and nasopharyngeal cancers.
Foundation Medicine研发的针对所有实体瘤的全面基因组测序(CGP)一次检测可以覆盖4种临床相关的基因变异类型,可检测315个癌症相关基因的整个编码序列,以及28个经常在实体肿瘤中发生重排的基因的内含子,为临床治疗靶点检测提供了重要手段。
在晚期NSCLC患者中,进行CGP检测,不仅可以检测已知的治疗靶点,还能发现其他新兴的治疗靶点;对于靶向治疗耐药的患者,可以探寻耐药机制;此外,对肿瘤突变负荷(TMB)的检测,可以预测患者能否从免疫治疗中获益。
主要内容:
·发现新兴治疗靶点
·探寻靶向耐药机制
·TMB检测
2017年10月12日
以上课程的观看地点均为【良医汇-肿瘤医生】App~
扫描二维码观看课程